Press Room - Sanofi US News

Media Room Menu

Home
Sanofi US News
Subscribe
Customer Service
Media Contacts

Month Year

Oct 2, 2026

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
Sep 10, 2026

Sanofi partners with USA Pickleball to launch “Serve Up Protection” campaign to help protect older adults from COVID-19 with NUVAXOVID™
Sep 8, 2026

Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
Jul 10, 2026

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Jun 12, 2026

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
May 28, 2026

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
May 18, 2026

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
May 5, 2026

DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study
Apr 22, 2026

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Apr 22, 2026

Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Apr 22, 2026

Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Apr 18, 2026

ESCMID: Sanofi’s NUVAXOVID™ COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Mar 28, 2026

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Mar 18, 2026

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Feb 25, 2026

Sanofi Becomes Official Supporter of the Boston World Cup 2026 Host City
Feb 17, 2026

Sanofi announces leadership evolution in Specialty Care Business Unit
Feb 9, 2026

Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
Feb 2, 2026

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
Jan 5, 2026

Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Dec 15, 2025

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

• Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed
Nov 4, 2025

ASH: new data reinforce Sanofi’s leadership in rare diseases and blood cancers
Oct 22, 2025

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Oct 20, 2025

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Oct 20, 2025

ESMO: AlphaMedix™ phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Sep 26, 2025

Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
Sep 11, 2025

Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sep 10, 2025

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
Aug 29, 2025

Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Jul 30, 2025

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
Jun 26, 2025

Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
Jun 25, 2025

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Jun 20, 2025

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Jun 9, 2025

Sanofi accelerates global shipping of BEYFORTUS® to prepare healthcare providers months ahead of 2025-2026 RSV season
Jun 7, 2025

RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color
Jun 6, 2025

ISTH: new data highlight innovation from Sanofi’s pipeline in rare diseases
May 22, 2025

Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
May 14, 2025

Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
Apr 18, 2025

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Apr 15, 2025

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
Apr 8, 2025

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Apr 3, 2025

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Mar 26, 2025

Chlamydia vaccine candidate granted fast track designation by the US FDA
Mar 25, 2025

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Mar 14, 2025

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
Mar 8, 2025

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Feb 18, 2025

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Jan 9, 2025

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Dec 13, 2024

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Dec 9, 2024

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
Dec 7, 2024

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Dec 3, 2024

ASH: New data underscore Sanofi's commitment to innovation in rare blood diseases and cancers
Nov 15, 2024

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Oct 24, 2024

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Oct 16, 2024

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals
Oct 16, 2024

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies
Sep 27, 2024

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Sep 20, 2024

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sep 20, 2024

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Sep 13, 2024

DUPIXENT® approved in the US as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps
Sep 11, 2024

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Sep 11, 2024

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Aug 8, 2024

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
Jul 17, 2024

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
Jul 10, 2024

Sanofi ships U.S. influenza vaccines for the 2024/25 season
Jun 27, 2024

CDC’s ACIP unanimously votes to add VAXELIS®, Sanofi and Merck’s pediatric hexavalent combination vaccine, to its preferential recommendations to help prevent invasive Hib disease in American Indian and Alaska Native infants
Jun 26, 2024

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Jun 11, 2024

Kevzara approved by FDA for the treatment of active polyarticular juvenile idiopathic arthritis
Jun 3, 2024

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
May 31, 2024

Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 27, 2024

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
May 22, 2024

New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma
May 20, 2024

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
May 13, 2024

Dupixent® sBLA accepted for FDA Priority Review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis
May 10, 2024

FDA approves updated ALTUVIIIO® label with expanded pediatric data confirming highly effective bleed protection in children with hemophilia A
Apr 26, 2024

New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
Mar 8, 2024

New data presented at AAD showcase continued commitment to advance treatments for inflammatory dermatologic diseases
Feb 24, 2024

Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
Feb 5, 2024

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Feb 1, 2024

Sanofi launches Beyfortus® (nirsevimab-alip) Reservation Program for 2024-2025 RSV season in U.S.
Dec 14, 2023

Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Nov 7, 2023

Sanofi to present clinical data reinforcing commitment to scientific innovation across blood cancers and rare blood disorders at ASH 2023
Nov 6, 2023

Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Nov 2, 2023

Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
Nov 1, 2023

Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
Oct 4, 2023

Phase 3 data demonstrating efficacy of Kevzara® (sarilumab) for patients with polymyalgia rheumatica published in NEJM
Sep 13, 2023

Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
- Photos 4
Aug 24, 2023

Beyfortus™ (nirsevimab-alip) recommended for routine use to protect infants against RSV disease in CDC Morbidity and Mortality Weekly Report

The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
Aug 3, 2023

U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jul 17, 2023

FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jun 8, 2023

FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
May 18, 2023

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
Mar 2, 2023

Sanofi launches R&D Consortium of industry and patient advocacy groups to accelerate medicines development
Jan 18, 2023

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Oct 6, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Aug 26, 2022

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report
Aug 12, 2022

Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations
Aug 3, 2022

Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare
Jul 26, 2022

Sanofi partners with Howard University in an unprecedented pharmacy fellowship program
Jul 1, 2022

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+

Show per page

Print
Email page
RSS